[{"Assets_0_FY_USD":520346000.0,"CommonStockSharesOutstanding_0_FY_shares":39373745.0,"EarningsPerShareBasic_1_FY_USD":-0.45,"EarningsPerShareBasic_4_FY_USD":-1.54,"EarningsPerShareDiluted_1_FY_USD":-0.55,"EarningsPerShareDiluted_4_FY_USD":-1.54,"NetCashProvidedByUsedInOperatingActivities_4_FY_USD":7403000.0,"NetIncomeLoss_1_FY_USD":-18000.0,"NetIncomeLoss_4_FY_USD":-59731000.0,"StockholdersEquity_0_FY_USD":293134000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":38769816.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":38769816.0,"Ticker":"TVTX","CIK":"1438533","name":"RETROPHIN, INC.","OfficialName":"Travere Therapeutics Inc. Common Stock","form":"10-K","period":"20171231","fy":"2017.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1905907401.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180227"}]